SEOM clinical guideline in ovarian cancer (2020)
-
A. Redondo [1] ; E. Guerra [2] ; L. Manso [3] ; C. Martin-Lorente [4] ; J. Martinez-Garcia [5] ; J. A. Perez-Fidalgo [8] ; M. Q. Varela [9] ; M. J. Rubio [6] ; M. P. Barretina-Ginesta [10] ; A. Gonzalez-Martin [7]
-
[1] Hospital Universitario La Paz
Hospital Universitario La Paz
Madrid, España
-
[2] Hospital Ramón y Cajal
Hospital Ramón y Cajal
Madrid, España
-
[3] Hospital Universitario 12 de Octubre
Hospital Universitario 12 de Octubre
Madrid, España
-
[4] Hospital de la Santa Creu i Sant Pau
Hospital de la Santa Creu i Sant Pau
Barcelona, España
-
[5] Hospital Virgen de la Arrixaca
Hospital Virgen de la Arrixaca
Murcia, España
-
[6] Hospital Universitario Reina Sofia
Hospital Universitario Reina Sofia
Cordoba, España
-
[7] Clínica Universitaria de Navarra
Clínica Universitaria de Navarra
Pamplona, España
-
[8] Hospital Clínico Universitario Valencia
-
[9] Complexo Hospitalario Universitario de A Coruña
-
[10] Institut d’Investigació Biomèdica de Girona
-
- Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 23, Nº. 5 (May), 2021 (Ejemplar dedicado a: SEOM clinical guidelines 2020), págs. 961-968
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
Despite remarkable advances in the knowledge of molecular biology and treatment, ovarian cancer remains the leading cause of death from gynecologic cancer. In the last decade, there have been important advances both in systemic and surgical treatment. However, there is no doubt that the incorporation of PARP inhibitors as maintenance after the response to platinum-based chemotherapy, first in recurrent disease and recently also in first line, will change the natural history of the disease.
The objective of this guide is to summarize the current evidence for the diagnosis, treatment, and follow-up of ovarian cancer, and to provide evidence-based recommendations for clinical practice.
